Literature DB >> 26972555

Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.

Céline Martel1, Fernand Labrie2, David F Archer3, Yuyong Ke1, Renaud Gonthier1, Jean-Nicolas Simard1, Lyne Lavoie1, Mario Vaillancourt1, Marlene Montesino1, John Balser4, Érick Moyneur5.   

Abstract

This study integrates all data obtained in women aged 40-80years enrolled with moderate to severe symptoms of vulvovaginal atrophy (VVA) who received daily intravaginal administration of 0.50% (6.5mg) dehydroepiandrosterone (DHEA; prasterone) for 12weeks (n=723; ITT-S population) as compared with placebo (n=266; ITT-S population). To this end, serum steroid levels (DHEA, DHEA-sulfate (DHEA-S), androst-5-ene-3β, 17β-diol (5-diol), testosterone, dihydrotestosterone (DHT), androstenedione (4-dione), estrone (E1), estradiol (E2), estrone sulfate (E1-S), androsterone glucuronide (ADT-G), and androstane-3α, 17β-diol 17-glucuronide (3α-diol-17G)) were measured at Day 1 and Week 12 by liquid chromatography-tandem mass spectrometry (LC-MS/MS) following validation performed according to the FDA guidelines [1-6]. In agreement with the mechanisms of intracrinology where DHEA is exclusively transformed intracellularly into active sex steroids which act and are inactivated locally before being released as glucuronided or sulfated metabolites for elimination by the kidneys and liver, all sex steroids remained well within normal postmenopausal values following administration of intravaginal DHEA. Serum estradiol, the most relevant sex steroid, was measured after 12weeks of treatment at 3.36pg/ml (cITT-S population) or 19% below the normal postmenopausal value of 4.17pg/ml. On the other hand, serum E1-S, the best recognized marker of global estrogenic activity, shows an average value of 209pg/ml at 12 weeks compared to 220pg/ml in normal postmenopausal women. Moreover, serum ADT-G, the main metabolite of androgens, also remains well within normal postmenopausal values. The present data shows that a low daily intravaginal dose (6.5mg) of DHEA (prasterone) which is efficacious on the symptoms and signs of VVA, permits to achieve the desired local efficacy without systemic exposure, in agreement with the stringent mechanisms of menopause established after 500 million years of evolution where each cell in each tissue is the master of its sex steroid exposure.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Androgens; Dehydroepiandrosterone (DHEA); Estradiol; Menopause; Prasterone; Vulvovaginal atrophy

Mesh:

Substances:

Year:  2016        PMID: 26972555     DOI: 10.1016/j.jsbmb.2016.03.016

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  13 in total

1.  Prasterone: A Review in Vulvovaginal Atrophy.

Authors:  Young-A Heo
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

2.  11-Ketotestosterone Is the Dominant Circulating Bioactive Androgen During Normal and Premature Adrenarche.

Authors:  Juilee Rege; Adina F Turcu; Josephine Z Kasa-Vubu; Antonio M Lerario; Gabriela C Auchus; Richard J Auchus; Joshua M Smith; Perrin C White; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2018-12-01       Impact factor: 5.958

Review 3.  Deconstructing the genitourinary syndrome of menopause.

Authors:  Pedro Vieira-Baptista; Claudia Marchitelli; Hope K Haefner; Gilbert Donders; Faustino Pérez-López
Journal:  Int Urogynecol J       Date:  2017-03-14       Impact factor: 2.894

Review 4.  Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.

Authors:  Elise D Cook; Elena I Iglehart; George Baum; Leslie L Schover; Lonzetta L Newman
Journal:  Menopause       Date:  2017-12       Impact factor: 2.953

5.  The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview.

Authors:  Cheryl Phua; Rodney Baber
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

Review 6.  Steroids in Stroke with Special Reference to Progesterone.

Authors:  Rachida Guennoun; Xiaoyan Zhu; Magalie Fréchou; Pauline Gaignard; Abdelhamid Slama; Philippe Liere; Michael Schumacher
Journal:  Cell Mol Neurobiol       Date:  2018-10-09       Impact factor: 5.046

Review 7.  Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function.

Authors:  Valentina Lucia La Rosa; Michał Ciebiera; Li-Te Lin; Shangrong Fan; Salvatore Butticè; Thozhukat Sathyapalan; Robert Jędra; Patricia Lordelo; Alessandro Favilli
Journal:  Prz Menopauzalny       Date:  2019-06-28

Review 8.  The Genitourinary Syndrome of Menopause: An Overview of the Recent Data.

Authors:  Kyveli Angelou; Themos Grigoriadis; Michail Diakosavvas; Dimitris Zacharakis; Stavros Athanasiou
Journal:  Cureus       Date:  2020-04-08

Review 9.  Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders.

Authors:  Douglas A Gibson; Ioannis Simitsidellis; Frances Collins; Philippa T K Saunders
Journal:  Int J Mol Sci       Date:  2018-10-22       Impact factor: 5.923

Review 10.  Vaginal Health in Menopausal Women.

Authors:  Stefania Alvisi; Giulia Gava; Isabella Orsili; Giulia Giacomelli; Maurizio Baldassarre; Renato Seracchioli; Maria Cristina Meriggiola
Journal:  Medicina (Kaunas)       Date:  2019-09-20       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.